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Abstract
Arsenic and Ultraviolet radiation B (UVB) are environmental toxins that have been
linked to various epithelial cancers. Arsenic metabolism in humans leads to its collection in the
skin, where it encounters and can act with known carcinogen UVB. Epidemiological evidence of
the two toxins demonstrates their potential to affect signaling pathways, with various
consequences. Here we employ an in vitro model system using Normal Human Epidermal
Keratinocytes (NHEK) to identify the effect of arsenic and UVB on humans and whether they
work synergistically. We find that although both cause induction of cyclin D1, culturing cells
with both co-mutagens does not lead to a potentiated effect. Evidence from other systems
indicates that both arsenic and UVB affect promoter activity in various ways, including
methylation. We undertook to examine the effects of arsenite and UVB on activation of the
cyclin D1 promoter related to changes in promoter methylation. While data had been
inconclusive in identifying methylation as the cause of cyclin D1 induction, emerging trends
seem to suggest an inverse relationship between methylation of the cyclin D1 promoter region
and induction of cyclin D1. Finally, we aimed to create a reporter construct capable of directly
demonstrating inductive effects of arsenic and UVB on the cyclin D1 promoter region through
luciferase activity. Preliminary results demonstrate that arsenic led to a two-fold increase in
luciferase activity, whereas UVB indicated that manipulation of the promoter region may not be
the cause of induction.
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Introduction
Overview of arsenic
Arsenic is an environmental toxin prevalent globally, including the US, China, India, and
Africa. Arsenic was a component in many insecticides, bactericides, fungicides, and
preservatives due to its toxicological properties. In many regions across the world a lead
arsenate-based pesticide has been used for decades. However, an increase in the awareness of the
oncogenic properties of arsenic lead to a reduction in the popularity of arsenic as a preservative
until it was completely banned in 2004 in the US (22). As a consequence, arsenic can now be
found in higher than normal doses, although not high enough to cause acute symptoms of arsenic
poisoning (23). Arsenic was also spread through chemical warfare, such as its use in lewisite (a
blister agent) (27) and agent blue, a deforesting herbicide used during the Vietnam War (26).
Arsenic is still widely used today and can be found in many locations, such as metal alloys (24,
27), chicken feed as Roxarsone (25), colors in paint (20), and taxidermy (21).
Arsenic has historically been considered a poison, but became a widespread public health
concern in the 20th century (17, 18). Arsenic poisoning is usually caused by ingestion of
contaminated water containing arsenicals or arsenic-containing compounds, although
consumption and inhalation are other sources of poisoning as well (39). Ground water and well
water have become high in arsenical content due to heavy soil contamination and rainfall that
causes export of arsenicals where it eventually ends up in the local water supply (24, 26, 27).
There is much ambiguity over what constitutes a ―safe‖ level of arsenic exposure. Current
US Environmental Protection Agency standards are currently set to 50 µg/L, and the estimated
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rate of death due to liver, lung, kidney or bladder cancer is 13 out of 1000 people (18). Recent
studies concluded that this exposure easily results in a combined cancer risk of 1 in 100 (18).
Globally, the World Health Organization has set the limits for arsenic exposure at 10 µg/L
currently, down from previous guidelines of 200 µg/L in 1958 (17). There is intense difficulty of
isolating the effects of arsenic exposure while excluding other environmental or external
influences. Further confounding these conclusions are the findings from animal studies. In mice,
arsenic has generally been found to be non-carcinogenic when administered alone, and is also
not seen to act as a tumor initiator nor tumor promoter (19).
Lethal acute arsenic poisoning can occur when inorganic arsenicals are ingested at levels
above 1mg/kg/day. Symptoms of acute non-lethal arsenic poisoning include vomiting, diarrhea,
hair loss, muscle cramping, pain and convulsions (16).
Chronic arsenic exposure begins to show its effects anywhere from five to 20 years after
exposure (17, 18). Symptoms of chronic arsenic exposure can be grouped into two categories;
non-cancerous and cancerous. Keratoses of the hands and feet, hyperpigmentation, diabetes
mellitus, and skin lesions are non-cancerous symptoms. Cancerous symptoms include cancers of
the breast (1-3), colon (4), bladder (17), and gastric cancer (4). For the remainder of this paper,
only cancerous effects of chronic arsenic exposure will be mentioned, although certain noncancerous diseases, such as hyperpigmentation, are hallmarks for chronic arsenic poisoning and
possible cancer development (35).
Chemical analysis of arsenic metabolism
There are three different classifications that arsenicals are categorized as: inorganic
6

arsenic, organic arsenic, and arsine gas (20). Arsenic is found in the environment as inorganic
arsenic sulfide (AssS3) and in soil and water. It is the 20th most abundant element in the Earth‘s
crust (24) and exists in two oxidation states: trivalent arsenite (As3+), such as arsenic trioxide and
sodium arsenite, and pentavalent arsenate (As5+), such as arsenic acid.
In mammals, arsenic‘s cytotoxicity is based on its current oxidation state and whether it
has been oxidized or not. Arsenate is much more cytotoxic than arsenite, and is immediately
reduced in humans, primarily in the blood and liver (19). Arsenite gets transported throughout
the body, mostly in hepatocytes, where it undergoes many steps of oxidization and methylation,
eventually ending up as dimethylarsenic acid (DMA), which facilitates excretion. This process is
costly, however, as it consumes much S-adenosylmethionine (SAM) and Glutathione (GSH).
The first step, reduction of arsenate to arsenite is done by many mammalian enzymes,
such as purine nucleoside phosphorylase (29) and G3P dehydrogenase (30) at the cost of GSH
(28). It is interesting to note that no matter the pathway used, a methylated intermediate is made,
that is then reduced by GSH. Once reduced to arsenite, arsenite methyltransferase (AS3MT)
catalyzes the addition of a methyl group (19). The next reaction is a two-step reaction that begins
with SAM as a methyl donor to methylate arsenite, followed by a reduction, which leaves
pentavalent monomethylarsonic acid (MMA5+). MMA5+ is reduced again prior to the addition of
another methyl group by GSH S-transferase Ω (GSTO) and AS3MT (45-47) (see Figure 1 (58)).
Metabolism of arsenic is costly, using up several equivalents of SAM and GSH, which will be
evaluated further.
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Figure 1: Structure of arsenicals through metabolic digestion in humans. Ingested arsenic-based
compounds undergo many modifications until they are excreted in humans. Although arsenite
and arsenate are common methods of ingestion, other organic arsenicals can be ingested, as seen
in the arsine-named compounds.
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Implications of arsenic metabolism
Ingestion of arsenic requires several equivalents of SAM and GSH to process and reduce
arsenic into a less toxic form, with eventual removal from the body. SAM is utilized for regular
cell methylation, including DNA methylation. DNA methyltransferase enzymes (DMNT) require
SAM as a cofactor to methylate DNA. Arsenic metabolism causes a depletion of DMNT activity
and presumably histone methylation activity as well (31-33).
AS3MT-mediated SAM depletion also causes a collection of S-adenosylhomocysteine
(SAH). High SAH accumulation can lead to inhibition of SAM through a negative feedback
loop, leading to an inhibition of SAM through another pathway (19, 28-30). SAH is recycled
back to SAM through a multi-step pathway that utilizes folic acid (as tetrahydrofolate) and
cobalamin (vitamin B12). These factors are obtained from dietary sources, linking lower
socioeconomic living standards to a decrease in SAM, which can trigger arsenic genotoxicity.
Arsenic has also been known to alter activities of cell cycle ‗gatekeepers,‘ such as p53
and p21. This is separate from ―signature mutations‖ caused by UV radiation (33). Arsenic
toxicity has been shown to cause p53 accumulation in patients suffering from arsenic-induced
Bowen‘s disease. Patients with wild-type Bowen‘s disease often underwent complete remission
after surgical operation, whereas patients with arsenic-induced Bowen‘s disease often have
recurrences (35). Histopathological analysis of patients with As-Bowen‘s disease demonstrated
high expression of mutated p53 (35, 39). Mutated p53 will be discussed further, and has
downstream implications that lead to unregulated cell cycle replication.
The literature shows a synergistic link between arsenic and UVB that leads to
9

potentiation of the carcinogenic effects of UVB (19, 38). Both toxins demonstrate effects on p53,
although UVB‘s effect is direct and will be discussed ahead.
Overview of UV Radiation
A major component of the light we receive from the sun is ultraviolet radiation. UV light
has found many uses in our society, such as tanning beds, sterilizing techniques (as black lights),
and in chemical reactions as lasers, due to its ability to excite electrons. UV is also required for
the metabolism of vitamin D (50), remaining biologically inactive in skin until contact with UVB
(51). Vitamin D is a necessary nutrient for balance and survival in the human body, and lack of
contact with sunlight can lead to ailments such as rickets and muscle pain (51). However,
although UV is becoming accepted for everyday use and is necessary for human life, there are
many harmful effects associated with it. An increase in levels of UV exposure has been linked to
sun burning, skin cancer, temporary and permanent eye damage, and several diseases. (51). At
the molecular level, UV exposure leads to DNA damage (33), protein mutation through amino
acid substitution (48), and the production of free radical oxygen species (53). UV radiation is
composed of three different types of wavelengths: UVA (320-400nm), UVB (290-320 nm), and
UVC (200-290 nm) (48). UVA tends to make up roughly 90-95% of the UV radiation that
arrives on earth, whereas most UVC rays are blocked and absorbed by ozone in the atmosphere
in a two-step reaction that both destroys oxygen and reforms ozone (48). They will not be further
discussed in this paper.
The rest of the UV radiation that arrives on earth is UVB. UVB has been implicated in
the epidemiology of many skin cancers, such as basal and squamous cell carcinoma (BCC/SCC),
and melanoma (33, 48-49), although some studies refute that claim (34). In the albino hairless
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mouse model, cancerous activity has been seen peaking at the 293 nm range. A significant but
smaller peak was seen at the 302 nm range in fish mutations, and they appear in the TP53 gene,
leading to a mutation in p53 protein (33, 48-49).
UVB and p53
p53 is a tumor suppressor gene that is activated through phosphorylation when DNA
damage is detected in cells. In its normal state, p53 binds to Mdm2, which promotes p53
degradation. Furthermore, mdm2 transcription is activated by p53, leading to a tightly regulated
negative feedback loop. Once phosphorylated, p53 binds to DNA and recruits transcription
factors, leading to p21 transcription. p21 is a cyclin-dependent kinase (cdk) inhibitor. This
interaction blocks the cdk-cyclin D1 interaction, which eventually leads to cell cycle arrest by
preventing phosphorylation of retinoblastoma protein (Rb). This will be mentioned further in the
next section. If a cell cannot be repaired p53 activates other transcription factors, leading to cell
apoptosis (52).
p53 is known as the ―guardian of the genome,‖ due to its importance in regulating cell
replication through apoptosis and cell cycle arrest (52). Epidemiological evidence has shown
several skin cancers to have high levels of mutated p53, establishing it as a cause for tumorigenic
growth. Brash et al. (48) established unique mutations in p53 as one of many steps which led to
development of SCC in patients, although p53 mutation is implicated in many cancers (19, 53).
p53 is tightly regulated by binding to mdm2, and mutated p53 generally appears in high levels in
patients due to an inability of mdm2 to bind to p53 and degrade it (54). These mutations also
lead to inability of p53 to bind to damaged DNA. This begins a cascade that allows unregulated
cell replication with damaged DNA; a proto-oncogenic process. Since mutated p53 will have no
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effect on the damaged DNA, p21 transcription will be halted, allowing phosphorylation of
retinoblastoma through a cdk-cyclin pathway, spearheaded by cyclin D1 (40, 52).
Cyclin D1
Cyclins are a family of holoenzymes which, when coupled to their kinases (cyclindependent kinases or CDKs), allow cells to undergo cell cycle progression. Four families of
cyclins exist: Cyclin D, E, A, and B and all are highly conserved (40). Their name is derived
from their activity, as cyclin proteins tend to oscillate throughout each phase in cell replication
(40). Each cyclin is constitutively transcribed at different times during the cell cycle, although
the D type family of cyclins is transcribed throughout the entire cell cycle. Furthermore, each
cyclin family has at least one kinase that it interacts with (cdk), although some cyclin proteins
interact with multiple kinases. Other cyclins will not be discussed further in this paper.
Cyclin D is encoded by the CCND gene and is present in many lower organisms such as
mice, drosophila, and chicken (55). Although the protein is highly conserved, humans contain 3
D type cyclins, Cyclin D1, D2, and D3 (40). All three of the D type cyclins interact with the
same kinases, CDK4 or CDK6. Our previous studies have identified cyclin D1 as an inducible
target after arsenic treatment (Appendix IVa) and will be focused on for the remainder of this
paper.
CCND1 is a gene a 4405 base pair gene located on chromosome 11 in humans (55, 56).
It is integral in cell cycle replication and interacts with cdk4 and cdk6 (40). Cyclin D1 is critical
in regulating the G1/S phase checkpoint through Rb phosphorylation. Once interacted, the
cyclinD1/cdk4 or cyclinD1/cdk 6 complexes phosphorylates Rb, breaking interaction with E2F
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and inactivating Rb. E2F recruits other factors, which allows passage into S phase and
progression of the cell cycle replication machinery. Production of cyclin D1 is tightly regulated,
and increased production of cyclin D1has been implicated in several cancers (40).

Rationale for studies on gene expression in human epithelial cells treated with
submicromolar levels of arsenic and UVB irradiation (Part I).
As previously mentioned arsenic demonstrates little mutagenicity or may not be
mutagenic at all when acting alone. However, in many areas with high levels of skin, breast,
colon, and gastric cancer, such as Bangladesh, China, and Taiwan, arsenic has been a common
toxin found that has previously been linked to cancer. Arsenic has been linked to the disruption
of several processes, but results are inconsistent due to arsenic showing antagonistic effects in
cells. At the supra-micromolar level (>1uM), arsenic mediates pro-apoptotic activities.
Interestingly, arsenic treatment is a method of curing certain cancers, such as chronic myelocytic
leukemia (19), where supra-micromolar levels of arsenic are used to induce apoptosis in cancer
cells.
At sub-micromolar levels (<1μM), literature has shown arsenic to induce cell
proliferation (39, 43). Experimental data on a line of SV-40 transformed human keratinocytes
(130 cells) demonstrated a stimulatory effect on cell proliferation at 400 nM levels of arsenic
(39). Through western blot analysis, arsenic was shown to increase levels of cyclin D1 in cells
treated with 400 nM concentration of arsenic (Appendix IVA). Furthermore, UVB-irradiation
has been shown to induce cell proliferation in murine keratinocytes and melanocytes (41, 42).
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To analyze the effects of arsenic and UVB-irradiation on the cyclin D1 gene, we
employed an in vitro system, using normal human epithelial keratinocytes as our model system.
We aimed to detect alterations in levels of gene expression of cyclin D1. To fulfill this objective,
we cultured NHEK cells and performed real-time PCR analysis, comparing levels of untreated
cells with cells cultured with arsenic, UVB, and a combination of the two test agents.

Rationale for studies on epigenetic regulation cyclin D1 expression by methylation in
human epithelial cells treated with submicromolar levels of arsenic and UVB irradiation
(Part II).
Epigenetic changes are changes that occur in genes by modifying nucleotides in DNA,
either directly or indirectly. Nanney (44) describes it as a system of cellular heredity based on
processes other than changes in DNA sequence. Specifically, DNA methylation, the form of
epigenetic modification discussed moving forward, targets the 5‘ end of a cytosine, attaching a
methyl group to carbon-5 in cytosine (Figure 2, 58). Methylation of cytosines in regions
identified as CpG islands in the promoter region constitutes a mechanism for regulation of gene
transcription in the cell.

Figure 2: Diagram of a cytosine
being before and after addition
of a methyl group. Methylation
is a method of epigenetic
regulation in the cell (Adapted
from Walsh, et al. (58)).
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Epigenetic changes are heritable, and are governed by DMNT activity. When the cell
replicates, methylation does not follow the synthesis of a daughter strand. Once the daughter
strand is synthesized, DMNT enzymes are responsible for methylating complementary cytosines.
Methylation is a well-known method of controlling gene expression in cells. When CpG islands
in the promoter are methylated transcription is generally reduced (19, 44). In the cyclin D1
promoter region, where transcriptional regulation of cyclin D1 production occurs, lie four
overlapping regions named the SP1 region (nt 102-145, Figure 3). This region is rich in CG sites,
which is where epigenetic silencing of cyclin D1 is thought to occur.

Figure 3: The cyclin D1 promoter and its transcriptional regulatory elements. CpG islands are
located in the four overlapping SP1 binding sites, and are our targets in bisulfite methylation
(13).
As previously mentioned, arsenic ingestion indirectly can lead to inhibition of DMNT
enzyme activity through cofactor limitation of SAM (19). Hypermethylation and
hypomethylation are both consequences of arsenic exposure (19), and both lead to epigenetic
damage. Hypomethylation of cyclin D1 can lead to an induction of cyclin D1 due to an increase
in availability of transcription factor binding sites. After demonstrating induction of cyclin D1
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through the use of real-time PCR, we aimed to determine whether epigenetic modification of the
cyclin D1 gene was a mechanism that led to increased levels of cyclin D1. To detect whether
methylation was a mechanism for induction, we employed the use of bisulfite treatment.
Treatment with bisulfite causes cytosines which are unmethylated to become uracils.
Unmethylated cytosines are binding sites for transcription factors which can lead to higher cyclin
D1 transcription, whereas methylated cytosines do not bind transcription factors. Furthermore,
both methylated and unmethylated cytosines can anneal to methylation specific primers, whereas
uracil-converted cytosines cannot (Table 1).

cd1meLS1R

CGGGCGCAGGGGGAGGGGGC

Annealing Location
(nucleotide designation
as per GB locus
Z29078)
28862905

cd1meLS1L

CTCCACCTCACCCCCTAAAT

26732692

cd1meLS2R

GGGAGCGGGAGGGGGGCGGGGG

29062927

cd1meLS2L

GGGCGATTTGCATTTCTATG

27652784

Primer Name

Nucleotide Sequence

Table 1: Primers used for bisulfite treatment quantification.
A reduction in Ct values after real time PCR are indicative of a larger availability of
binding sites, due to a reduction in methylation.

Rationale for the development of a method of detecting cyclin D1 induction through a
reporter gene.
After determining that cyclin D1 was being induced once exposed to arsenic and UVB
irradiation, we sought to determine a method of detecting differences in cyclin D1 directly from
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cells. Luciferase is an enzyme that, in the presence of substrate and ATP, gives off visible light
(Figure 4a). We employed pGL2, a plasmid containing Luciferase with the aim of subcloning the
cyclin D1 promoter region into the plasmid to directly detect cyclin D1 production (Figure 4b).

Figure 4a: Schematic of Luciferase activity. Once
the pGL2 plasmid is transfected into our cells,
substrate containing ATP and Luciferin is added
before placing the cells into the GLOmax
luminescence reader (59).

To create a reporter that was capable of demonstrating luminescence in the presence of
cyclin D1, we synthesized a construct containing the cyclin D1 promoter region (figure 4c), and
subcloned it adjacent to the luciferase gene in pGL2. Once synthesized, the pGL2/cyclin D1
construct would synthesize luciferase in the presence of cyclin D1 transcription factors. Thus, the
plasmid can be utilized as a reporter gene in the presence of its substrate (Luciferin/ATP).

Figure 4b: Map of the pGL2-Basic vector.
The vector is 5598 base pairs long, and
contains ampicillin resistance. Cyclin D1
segment was inserted at the 18 base pair
region (Promega, Milwaukee, WI) (60).
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Figure 4c. Map of synthesized plasmid
containing the cyclin D1 promoter region
flanked by SacI excision sites. The
segment is 1000 base pairs long.

Originally, we set out to isolate the cyclin D1 promoter region through qPCR. As
previously shown, the cyclin D1 promoter region precedes the binding site of the promoter by 29
nucleotides (Figure 3). Using primers targeted at this region (Table 2), we aimed to isolate the
promoter region, and clone it into our pGL2 vector. The cyclin D1 gene is 4585 nucleotides long,
with the promoter region ranging from 2015 – 2981 nucleotides. Primers annealed at nt 1935 or
1966, and terminated at 3015, yielding a segment that was either 1080 or 1049 nucleotides long
(Table 2, Figure 7). After isolation, the aim was to subclone the cyclin D1 promoter region
segment into our pGL2 vector; however complications arose in ligating the two segments
together.
Primer Name

Nucleotide Sequence

Annealing Location

AP1L1

CAGTCCCAGGGCAAATTCTA

19351954

DF

ACGTCTACACCCCCAACAAA

19661985

CYCD1PRR

CTCCAGGACTTTGCAACTTCAACAAAACT

29873015

Table 2: Primers used for amplification of the cyclin D1 promoter elements.
To continue the experiment, we synthesized the cyclin D1 promoter region into a
plasmid, flanking the promoter region with Sac I restriction digest sites (Figure 4b). The pGL218

Basic vector only contains one Sac I binding site, linearizing the plasmid. Once subcloned, the
synthesized plasmid was transfected into our 130 cell line (SV40-immortalized human
keratinocytes) using Lipofectamine 2000 as the transfection reagent. Once transfection was
complete, we treated these cells with arsenic or UVB-irradiation. If arsenic or UVB radiation led
to an increase in transcription factors, this should also lead to an increase in luciferase activity
and luminescence.
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Methods
Experimental Preparations for Parts I and II
 Preparation of media
Epilife medium (Life Technologies, Norwalk, CT) was used to culture keratinocytes.
Before cell culturing, Epilife medium is supplemented with 10ml Human Keratinocyte Growth
Serum 500x (HKGS) (Life Technologies, Norwalk, CT), and 5 ml Pen/Strep Amphotericin B
(Cambrex Bio Science, Walkersville, MD). Cell cultures in prior experiments demonstrated
better growth when treated with 10ml 100x HKGS. Once prepared, cell medium is used to treat
keratinocytes. This is NHEK complete medium.
 Unfreezing cells
Normalized human epithelial keratinocytes (NHEK) (Invitrogen, Grand Island, NY) were
stored in liquid nitrogen until use. Cell vials were thawed in a 37°C bath for two minutes, then
placed into 5ml of NHEK complete and centrifuged at 3000rpm in a tabletop centrifuge for five
minutes. After centrifugation, supernatant was discarded and the pellet was resuspended in 9ml
Epilife medium to be placed into 3 25cm2 flasks (T-25 flask). Pellet was thoroughly resuspended,
and evenly divided into flasks. Cells were placed in T-25 flasks while passages were being
expanded. Passage 3 or passage 4 cells were utilized for experimental conditions.
 Cell culture for growth and cell splitting
Cells plated in T-25 flasks were grown in Epilife complete medium, with medium
changed every 2 days until cells reached 90% – 100% confluency. Once high confluency was
achieved, medium was removed and cells were washed in 1ml Trypsin-EDTA (0.26% Trypsin
lacking Calcium and Magnesium, with 1 mM EDTA (MP Biomedicals, Solon, Ohio)), then
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incubated in 2ml Trypsin-EDTA for 6 minutes or until visibly detached from the monolayer.
Trypsin was neutralized by adding 7ml NHEK Complete medium. Samples were centrifuged at
3000 rpm for 5 minutes and supernatant was subsequently discarded. Cells were resuspended in
5ml NHEK complete medium and centrifuged again at 3000 rpm for 5 minutes. Supernatant was
discarded, and cells were resuspended in NHEK medium, pending passage. Passage 1 and
passage 2 cells were resuspended in 9ml, and distributed into 3 T-25 flasks for culture. Passage 3
and 4 cells were resuspended in 24 ml NHEK complete and distributed evenly into 6-well trays
to be treated with experimental conditions in accordance to the experiment performed.
 Experimental cell culture treatment
Plated cells were treated under standardized conditions in 6 well tissue culture trays.
Epilife Complete was used to culture the cells. Cells were typically harvested 8 or 9 days after
plating. Once cells reached 20% confluence, colonies were exposed to experimental conditions.
Wells initially exposed were labeled as ―5 day‖ treated cells, and labeled according to conditions
(treated with NHEK complete infused with 400nm sodium arsenite (As) or normal Epilife
complete medium, and either subjected to 5.7mJ/cm2 of UVB irradiation (UVB) from an FS20
light source (5.7 mJ/cm2) or no irradiation. Cells cultured with arsenic were maintained in
arsenic-infused NHEK complete. Irradiated cells were exposed to UVB at only one instance.
Untreated wells were refreshed with 2ml Epilife Complete. Treatments were continued two days
later at ―3 day‖ and ―1 day‖ time point. Once cells were 85% - 90% confluent, 24 hours after the
―1 day‖ time point, RNA was extracted.
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Methods for Part I
 RNA isolation
RNA was extracted using Total RNA Isolation Kit (Promega, Milwaukee, WI). For RNA
extraction, cell culture medium was removed from the well via aspiration. Cell monolayers were
quickly and subsequently rinsed twice using cold, autoclaved 1x phosphate-buffered saline
(PBS). Once rinsed, trays were treated with 175 µl of RNA Lysis Buffer (+ β-mercaptoethanol),
causing cells to lyse and buffer to coagulate. The trays were then treated with RNA Dilution
Buffer and collected in microcentrifuge tubes. Microcentrifuge tubes were subsequently heated
to 70°C for 3 minutes, and centrifuged at 14000 rpm for 1 minute. Supernatants were collected
and placed into new microcentrifuge tubes, followed by addition of 200 µl 95% ethanol USP.
This mix was then transferred into a spin basket assembly and centrifuged at 14000 rpm for 1
minute. Once finished, eluates are discarded and centrifuged again with 600 µl of RNA Wash
Solution (supplemented with ethanol) for 1 minute. Eluates were again discarded. Spin baskets
were then treated with 50 µl DNase incubation mix (5 µl 0.09 M MnCl2, 5 µl DNase I, and 40 µl
Yellow Core Buffer) for 15 minutes. 200 µl of DNA Stop Solution (+ ethanol) was added to
arrest the reaction, followed by centrifugation for another minute. 600 µl of RNA Wash Solution
was then added and centrifuged for 1 minute, and rinsed again with 250 µl RNA Wash solution,
followed by a two minute wash. Once finished, the baskets were transferred to microcentrifuge
tubes and treated with 100 µl nuclease-free water, and incubated for 1 minute. Finally, samples
are centrifuged for 1 minute, and eluate is collected and stored at -70°C.
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 cDNA Synthesis
cDNA was synthesized using the Protoscript® First Strand cDNA Synthesis Kit (New
England BioLabs, Ipswitch, MA). Microcentrifuge tubes were filled with 2 µl primer dT23VN, 1
µg of RNA (ranging from 1-6 µl of RNA), and brought up to 8 µl with nuclease-free water. The
mix was heated at 70°C for 5 minutes, then centrifuged in a microfuge at 14000 rpm briefly and
placed on ice. To these mixes, 10 µl of M-MuLV Reaction Mix was added, followed by 2 µl of
M-MuLV Enzyme mix containing reverse transcriptase, for a final volume of 20 µl. The
mixtures were incubated at 42°C for 1 hour, and raised to 80°C for 5 minutes to inactivate the
enzyme. Finally, solutions were diluted to 50 µl by adding 30 µl more nuclease free water, and
stored at -20°C.
 PCR
The cDNA synthesized was tested via bench-top PCR. The protocol used for the PCR is
as follows: An initial denaturation state of 94°C for 30 seconds, followed by an annealing step of
60°C for 30 seconds and an extension step of 68°C for 30 seconds, each for 30 cycles, then
finished with a final elongation at 72°C for 5 minutes. The PCR mixture was composed of 5 µl
5x PrimeStar Buffer, 2 µl dNTP mix, 1 µl of forward primer CCND1R, 1µl of reverse primer
CCND1L, .5 µl PrimeStar Taq polymerase, 1 µl of cDNA template, and water to bring the
solution up to 50 µl (35.5 µl) After the PCR, a 2% agarose gel containing ethidium bromide was
used to detect DNA by fluorescence using a transilluminator.
 Real-Time PCR to identify alterations in cDNA
Real-Time PCR (RT-PCR) was used to quantify induction of cyclin D1. To track RT23

PCR amplifications we used SYBR Green (Thermo Scientific Abgene, Abgene House, Blenheim
Road, Epsom KT19 9AP, UK) to detect DNA concentration. Reactions were filled with 10 µl of
SYBR Green, 2 µl of left primer CCND1R, 2 µl of right primer CCND1L and 6 µl of cDNA
synthesized from a previous step.
The cycling protocol used for the RT-PCR was an initial heat step of 95°C for 15
minutes to activate the enzyme. Next, a denaturing step of 95°C for 15 seconds, followed by an
elongation step of 60°C for 10 seconds was performed for 40 cycles. Once finished, data was
subsequently collected. Melting curves were added to account for possible primer dimerization
and data was collected. Ct values collected were then fit into the equation 2-(Ct). A lower Ct value
indicated more cell proliferation.
Methods for Part II
 DNA Extraction
Cultured cells exposed to experimental conditions cells were aspirated and treated with 1
ml 0.26% Trypsin-EDTA to rinse off excess medium and retreated with 2 ml trypsin, followed
incubated at room temperature for 6 minutes or until detached from the monolayer. Trypsin was
neutralized by adding 7ml NHEK complete medium (Epilife, Invitrogen, Carlsbad, CA).
Samples were centrifuged at 3000 rpm in a tabletop centrifuge for 5 minutes and supernatant was
subsequently discarded. Cells were resuspended in 800 µl 1x PBS and transferred to a
microcentrifuge tube. Cells were centrifuged at 3500 rpm for 5 minutes, and supernatant was
discarded followed by resuspension in 200 µl 1x PBS. DNA was extracted according to the
DNeasy cell & tissue kit (QIAGEN Sciences, Germantown, MD). To each sample, 20 µl
proteinase K was added followed by 200 µl buffer AL, then vortexed. Cells were incubated for
24

10 minutes at 56°C. After incubation, 200 µl of 95% ethanol USP was added and mixed by
vortexing. The mixture was then transferred to a sealed DNeasy Mini-spin column and
centrifuged at 8000 rpm for 1 minute. The collection tube was then discarded, and replaced with
an unused collection tube. 500 µl AW1 buffer is then added to the spin column, followed by a
centrifugation at 8000 rpm for 1 minute. The collection tube was discarded, and replaced with an
unused tube, followed by an addition of 500 µl AW2 to the spin column, and centrifuged at
14000 rpm (20000 xg) for 3 minutes. The spin column is then transferred to a new
microcentrifuge tube, and 200 µl of nuclease free water was added. After 1 minute of incubation,
reactions were centrifuged for 1 minute at 8000 rpm for DNA yield. DNA was quantified using a
ThermoScientific Nanodrop Spectrophotometer (Thermo Fisher Scientific, Waltham, MA).
 DNA Methylation/Bisulfite Conversion
Once DNA was isolated from NHEK cells, concentrations were analyzed using a
Nanodrop. Concentrations were normalized to 500 ng/20 µl. Bisulfite conversion was performed
with the EZ DNA Methylation-Gold KitTM (Zymo Research, Irvine, CA). Ct conversion reagent
was prepared by adding 900 µl nuclease-free water, 300 µl of M-dilution buffer, and 50 µl of Mdissolving buffer to a tube of Ct conversion reagent. The mixture was then vortexed for 10
minutes. M-wash buffer was prepared by adding 24 ml of 100% ethanol to 6 ml of M-wash
buffer, and mixed. 130 µl of Ct conversion reagent was added to 20 µl of DNA containing
500 ng of DNA and mixed. The samples were then placed in a thermal cycler that performed the
following steps: 98°C for 10 minutes, 64°C for 2.5 hours, and 4°C 20 minutes (but could be
stored for 20 hours). 600 µl of M-Binding buffer was then added to a Zymo-spinTM IC column,
followed by the sample, which was then added to the column. The columns were inverted several
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times, and centrifuged at 14000 rpm for 30 seconds. Flow through was discarded, and 100 µl of
M-wash buffer (+ ethanol) was added, and then centrifuged for 30 seconds. 200 µl of
M-desulphonation buffer was added to the column and incubated at room temperature for 20
minutes, then centrifuged at 14000 rpm. 200 µl of M-wash buffer was then added to the column
and centrifuged at 14000 rpm for 30 seconds, then repeated again. Finally, the column was
transferred to a microcentrifuge tube, where 10 µl of M-elution buffer was added to the column
and centrifuged for 30 seconds. DNA was stored at -20°C.
 Real-Time PCR to identify changes in DNA by bisulfite conversion
Once DNA was converted, Real-Time PCR (RT-PCR) was subsequently used to detect
whether C  U conversions occurred. To track RT-PCR amplifications we used SYBR Green
(Thermo Scientific Abgene, Abgene House, Blenheim Road, UK) as the dye to detect DNA
amplification. The reaction mixtures were composed of 10 µl of SYBR Green, 2 µl of left
primer, 2 µl of right primer, and 6 µl of a combination of 250ng DNA and nuclease free water
(Primers on Table 1).
The cycling protocol used for the RTPCR was 40 cycles of 94°C for 15 seconds, 60°C for
45 seconds, and 72°C for 2 minutes. The Ct values collected are then again fit into the equation
2-(Ct). Gel electrophoresis is then performed to test PCR products.
Methods for Part III
 Preparation of media
For this set of experiments, we used immortalized SV40-transformed human
keratinocytes (Line 130 cells). The medium used to culture these cells was Dulbecco‘s Modified
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Eagle Medium (Life Technologies, Grand Island, NY) supplemented with 100 ml Fetal Bovine
Serum, 1 ml hydrocortisone and 6ml of Pen/Strep Amphotericin. This was a complete medium.
 Maintenance of cell culture
Line 130 cells were cultured in a similar fashion to NHEK cells previously mentioned.
As these cells were immortalized, passage number was noted but not taken into account with
regards to performing experiments. Cells were refreshed with DMEM media at identical rates as
NHEK cells above. Experiments were performed in 6-well trays.
Isolation of the cyclin D1 transcriptional regulatory region
 Cloning of the cyclin D1 regulatory region
Line 130 cells were grown until 90% confluence. DNA extraction was performed using
the same methods and protocol above. Samples were cloned using bench top PCR, utilizing
primers flanking the cyclin D1 transcriptional region (Table 2). Samples were run on an
analytical gel to test for proper cloned segment length.
 Gel purification of the cyclin D1 transcriptional region
Cloned samples were run on 1% agarose gels and purified as according to the Qiagen Gel
Purification Kit (Qiagen Inc., Valencia, CA). Samples were excised from agarose gels and
weighed, followed by addition of 3 units of QG buffer for every mg of agarose followed by
incubation at 50°C for 10 minutes. Isopropanol 100% USP was then added equal to 1 unit of
agarose, and the preps were pipetted into a spin column. Samples were centrifuged at 13000 rpm
for 1 minute and flow through was discarded. Samples were then washed with 750 µl Buffer PE
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with Ethanol and centrifuged again at 13000 rpm for 1 minute. Samples were spun again to
eliminate excess buffer prior to final isolation step. Finally, 50 µl of EB buffer was added to each
sample and centrifuged for 1 minute. DNA was tested on a 1% agarose gel to confirm segment.
 Replication of plasmids
For cloning of plasmids the plasmid constructs were transformed into competent E. coli,
and the bacteria were plated onto solid agar. Ampicillin resistant colonies were selected, and
growing colonies were isolated and placed into liquid culture containing 5ml Luria Broth
supplemented with 500 µg Ampicillin, and incubated in a shaker overnight. Plasmids were
isolated according to Promega DNA Isolation kit (Promega Corporation, Madison, WI). Samples
were centrifuged at 3000 rpm for 10 minutes and supernatant was discarded. Pellets were
resuspended in 250 µl Cell Resuspension Solution. 250 µl of cell lysis solution was then added
followed by 4 µl of Alkaline Protease Solution and allowed to incubate for 5 minutes. After
incubation, 350 µl of Neutralization solution was added and mixed, followed by centrifugation at
14,500 rpm for 10 minutes. Lysates were pipetted into a spin column and centrifuged for 1
minute at 14,500 rpm. After, samples were washed with 750 µl and 250 µl of Wash solution
(+ethanol) for 1 minute each time. Samples were centrifuged again for 2 minutes to ensure
elimination of wash solution. Finally, spin columns were placed in microcentrifuge tubes and
100 µl of nuclease-free water was added, followed by centrifugation. Concentrations were
attained using a Thermoscientific Nanodrop Spectrophotometer.
 Transfection
Once cells had achieved 75% confluence, cultures were treated with Lipofectamine 2000
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(Life Technologies, Grand Island, NY) as a transfection reagent. Samples were prepared as
follows: for each culture, two 1.5 ml microcentrifuge tubes were filled with 250 µl Optimem®
Reduced Serum Media (Life Technologies, Grand Island, NY) media. To one set of tubes, 2 µg
of plasmid transfect was added. To the other set, 4 µl of Lipofectamine 2000 was added. Both
sets were incubated for 5 minutes. After incubation, tubes were combined into one
microcentrifuge tube containing 500 µl Optimem medium, 4 µl Lipofectamine 2000, and 2 µg of
plasmid DNA, and were incubated for 20 minutes. Samples to be treated were washed with 1.5
ml Optimem medium three times, and filled with 1.5 ml Optimem media. After incubation,
transfection preps were added to cultures.
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Results
Part I Results
The first question we set out to determine was the effect of arsenic and UVB on cyclin
D1 in our human keratinocytes. In every condition, changes in gene expression were observed.
As the duration of exposure to mutagen increased, levels of induction changed accordingly.
Arsenic exposure caused an average of 187% induction of cyclin D1 when compared to the
control. Induction increased with exposure to Arsenic, resulting in an average of 220% induction
after 3 days of exposure, and 261% induction after 5 days of arsenic treatment. Similar trends
were evident in samples treated with 5.7mJ/cm2 of UVB irradiation. After only 1 day of
treatment, an average of 293% induction of cyclin D1 was evident. At the 3 day time point 572%
induction was seen, with a dramatic 1140% induction of cyclin D1 at the 5 day time point.
Once induction of cyclin D1 was demonstrated in cultures treated with and without
arsenic, the next step was to combine the test agents, and determine whether the effects of
arsenic and UVB worked synergistically to potentiate the effects of induction of cyclin D1.
Originally, our group combined the test agents at a ratio of 100% (400nm of arsenic and
5.7mJ/cm2 of UVB irradiation) and treated cells with both test agents simultaneously at either the
1, 3, or 5 day time points. Contrary to previous data, levels of induction decreased as duration of
exposure increased, until the 5 day time point, where down-regulation had occurred. Cells
harvested after 1 day of treatment demonstrated an average of 398% induction of cyclin D1. This
was the highest value of induction at the one day time point. When cultured for 3 days, induction
levels had dropped to 134%, followed by a reduction of cyclin D1 after 5 days of incubation
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Figure 5: Relative quantitation of cyclin D1 expression at various times after UVB irradiation or
arsenite treatment. NHEK cells were treated with 400 nM sodium arsenite and/or 5.7mJ/cm2 of
UVB irradiation, and cultured for a number of days until harvest. All data points have been
analyzed by real-time PCR, and Ct values obtained were raised to 2(-Ct). Calculated values were
subsequently weighed against controls: 2(-Ct) value of treated culture 2(-Ct) value of control with
equal time point. Untreated cultures are considered control, and are normalized to 100%. Positive
values (above 100%) indicate induction, and negative values (under 100%) indicate down
regulation of cyclin D1 after treatment. All cells were the same passage and grown for the same
amount of time. Treatment with test agents occurred at 1, 3, and 5 days time points, and cultures
were harvested on the 6th day. Cells were treated with 400nm arsenic, 5.7mJ/cm2 (4 minute) of
UVB, or a combination of the two. 200nm Arsenic, 2.8mJ/cm2 (2 minute) UVB cultures were
treated with both conditions, halving exposure to the co-mutagens when cultured together.
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Since induction of cyclin D1 began with the potentiating effects we hypothesized,
followed by subsequent decreasing levels of induction until reduction was observed, we decided
to alter test agents levels. Since both test agents are known to cause damage at the genetic and
molecular level, an accumulation of toxicity could be the reason that varying trends were
observed. As a consequence we attempted the same experiment with decreased levels of arsenic
(200nm) and exposure to 2 minutes of UVB (2.8mJ/cm2) (Figure 5). After a day of treatment,
high levels of induction were seen, averaging 338%, which was higher than both isolated arsenic
and UVB irradiation treatment at the 1 day time point. At the 3 day time point, 398% induction
was seen, followed by an average of 889% induction at the 5 day time point.

Results: Part II
Our next aim was to determine whether methylation was a possible mechanism that led to
induction of cyclin D1 in human keratinocytes. Average values and number of data points per
averaged value ranged per experiment (Appendix Table Ib). Control values were typically grown
for equal time lengths, and should have had similar values. Although the 3 day and 5 day time
points had similar values (35% and 34%, respectively), the 1 day control time point was radically
different, with an average of 2%. Arsenic-treated keratinocytes demonstrated an average of 80%
reduction in methylation, lowest at the 1 day time point with 15%, followed by 20% on the 3 day
time point, and 23% reduction after 5 days, demonstrating a slight upward trend for cells treated
with arsenic. Finally, cells irradiated with UVB demonstrated no clear trends. There was a 59%
change in cells treated with UVB irradiation after 1 day of treatment, 14% change 3 days after
irradiation, and an 86% change 5 days after irradiation.
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Figure 6: Relative quantification of cyclin D1 promoter methylation at various times after UVB
irradiation or arsenite treatment. NHEK cells were treated with 400 nM sodium arsenite or
5.7mJ/cm2 of UVB irradiation, and cultured for various periods of time up to 5 days until
harvested. All samples were run in real-time PCR with methylation-specific primers, and RQ
values were determined as 2(-Ct). Calculated values were weighed against their untreated
corresponding value: Treated 2(-Ct) value/Untreated 2(-Ct) value. Appendix Table Ib shows
individual graphed data points.

Our preliminary results (Appendix IVB, IVC) had demonstrated a time-dependent
decrease in methylation and established potential trends; however our results have not been
consistent with that hypothesis. In performing our bisulfite conversion experiments, we ran into
several issues. In our experiments, many values have been non-detectable. Furthermore, severe
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range in values is the cause for large margins of error, and is due to non-detectable Ct values.
This may be due to DNA fragmentation which may occur after bisulfite treatment. To test this,
we used primers which annealed to promoter segments lacking cytosine residues.

Primer Name

Nucleotide Sequence

Annealing Location

Frag1969F

TCTACACCCCCAACAAAACCAATTA 19691993

Frag3443F

CTACTCACCCCCCTCCCTTCTCTCCC 34433468

Frag3541R

ACCCCCACCCCTTCCTCCTTCA

35193541

Frag3586R

ACCCCCTTCTCCCCTCCCAC

35673586

Table 4: Fragmentation Primers. Primers are void of CpG island pairings to test for
fragmentation in DNA after bisulfite treatment.
Bisulfite treatment is known to demonstrate DNA fragmentation when used to convert
unmethylated cytosines to uracils. To determine if this was an issue in our experiment, PCR
targeting non-CpG islands was used to analyze length before and after bisulfite treatment.
Unpublished data has demonstrated large amounts of fragmentation occurring after treatment,
pointing to this as a possible reason that Ct values are appearing with such disparity in all
samples. Instead of demonstrating cloned segments in the 1.5kb range, we are seeing large
smears of DNA, indicative of fragmentation.
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Part III Results
The final goal of our project was to develop a method of detecting cyclin D1 induction
through a reporter gene. We began first with cloning the 1080 or 1045 bp promoter segments
amplified using primers cd1meLS1R and cd1meLS1L (see Table 1 in Rationale for part III).
These segments contained the cyclin D1 regulatory promoter region, which would be subcloned
into pGL2. As seen in figure 7, cyclin D1 segments were successfully cloned via bench top PCR
and isolated. However, due to issues with ligating the cyclin D1 promoter region into the pGL2
plasmid, a plasmid containing the cyclin D1 promoter region flanked by SacI sites (Appendix
IIIb) was synthesized commercially by GeneArt (Life Technologies, Norwalk, CT). Once
excised, the cyclin D1 promoter was subcloned into pGL2, yielding plasmids. Plasmids were
digested with SacI, yielding 3 successful plasmids (Figure 8).

AP1L1CYCD1PRR

M1

DFCYCD1PRR

1000
750
500
300
150
50

Figure 7: PCR results of various regions in the cyclin D1 transcriptional regulatory region.
Highlighted squares refer to primers noted above the well. Marker used was PCR marker.
AP1L1CYCD1PRR = 1080 bp length | DFCYCD1PRR = 1059 bp length
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23kb
9.4kb
6.5kb
2.3kb
2.0kb
564bp

Figure 8: SacI Digestion of pGL2 Plasmids subcloned with the cyclin D1 promoter region.
Marker used was HindIII. pGL2/Cyclin D1 combined plasmid = 6599, cyclin D1 promoter
region segment = 1001 bp. Only wells 3, 8, and 9 were utilized out of 10 plasmid preps.
**Plasmids represented by 3, 8, and 9 are termed PGL/CD1, PGL/CD2, and PGL/CD3,
respectively.
The next phase of our experiment was to establish quantity of plasmid to add when
performing transfections. Transfection with Lipofectamine 2000 regularly required a limit of 1
µg plasmid. This quantity of plasmid worked consistently when comparing our positive and
negative controls. However, our subcloned plasmids would demonstrate poor luminescence,
perhaps due to the newly subcloned cyclin D1 fragment. Concentration was increased to 2 µg of
DNA per transfection, and results were compared and analyzed (Figure 9). The pGL2-Control
vector was a plasmid similar to the pGL2-Basic plasmid but contained an SV40 promoter and
enhancer, for constitutive expression of luciferase (Promega, Milwaukee, WI).
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Figure 9: Luminescence values for transfected cells containing pGL2/cyclin D1 plasmid
construct. 130 cells were transfected and harvested after 3 days with either 1 µg or 2 µg of
plasmid DNA. Plasmids PGL/CD1, PGL/CD2, and PGL/CD3 were tested to identify viability of
the plasmid construct. Negative controls were cells transfected with pGL2 plasmid lacking the
cyclin D1 promoter, and positive controls were cells transfected with a pGL2 control promoter
containing SV40 promoter and enhancer. Triplicates were run and averaged. In all experiments
performed, empty wells had a baseline luminescence average of 3.0x101, and media without cells
had a luminescence average of 2.7x101. Positive control value is 2.9x103, significantly higher
than other results. Y-axis is truncated for better visibility.
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Figure 10: Luminescence values for transfected cells containing pGL2/cyclin D1 plasmid
construct. 130 cells were treated with 400 nM sodium arsenite or 5.7mJ/cm2 of UVB irradiation,
or were left untreated, and cultured for 3 days before harvest. Results are the average of
triplicates. Negative controls were untransfected cells and positive control were cells transfected
with a pGL2 control promoter containing SV40 promoter and enhancer. Triplicates were run and
averaged. In all experiments performed, empty wells had a baseline luminescence average of
3.0x101, and media without cells had a luminescence average of 2.7x101.
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Once viable transfections were visible, our group decided to treat transfected cells with
our conditions. Since this is a preliminary experiment, we utilized the 3 day time point for our
initial experiment. The 3 day time point coincided with our typical transfection protocol, and did
not alter incubation time drastically. After transfection, cells were placed in DMEM, and treated
with either UVB or arsenic. All cells were harvested 3 days later. In our negative control, cells
gave off a luminescence value of 2.7x101, consistent with our baseline values for wells that were
empty or contained DMEM only. Our positive control gave a much higher luminescence,
averaging in at 1.6x102. Values for untreated cells containing transfected plasmid averaged
4.3x102. Samples incubated with arsenic over the 3 day period had an average value of 8.0x102,
nearly double the untreated sample, and exhibiting an increase in luciferase production. This
trend however was not consistent in our samples treated with UVB irradiation. Values observed
were only 1.9x102, higher than our positive control, but lower than the untreated samples.
Our reporter construct demonstrated that arsenic, but not UVB, is affecting cyclin D1
induction through interaction with the cyclin D1 promoter region. The next step will be to
remove segments of the promoter region to determine where this interaction with arsenic is
occurring (Figure 11). This will be further elucidated in the discussion.
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Discussion
At the outset it was our goal to determine whether transcription of cyclin D1 was induced
by arsenic and/or UVB radiation. Previous findings had shown that cyclin D1 was induced when
treated with arsenic at submicromolar levels. These results were now extended to UVB
irradiation. Cyclin D1 was induced in almost all experimental conditions, with a marked timedependent increase in cyclin D1 induction when treated with arsenic or UVB. In samples treated
with only arsenic, induction was seen at 2-fold levels, from 87% induction to 160% total
induction. In our samples treated with UVB, the induction and the trends were much more
drastic. After only 1 day of treatment, nearly 3-fold levels of induction were observed. This
increased to 472% total induction after 3 days, and an average of 1000% induction. Thus, UVB
irradiation led to increased cyclin D1 transcription levels.
We also wanted to examine the effects of co-mutagen treatment. A number of previous
studies have indicated synergistic activity between arsenic and UVB-irradiation (19, 38, 39, 43,
45, 46). These agents, when combined, should provide a potentiated effect on induction greater
than the observed induction in arsenic and UVB-treated samples. We began by combining our
arsenic and UVB treatment conditions, and detecting levels of induction. We demonstrated high
levels of induction after 1 day of treatment when treating samples with both test agents, with
nearly 3-fold levels of induction. However, visible trends led to a decline in cyclin D1 induction,
culminating with an average down-regulation of cyclin D1. As cells were cultured for longer
periods of time after treatment with arsenic and UVB, cell viability also seemed to decline (data
not shown). Possible reasons for loss of viability and loss of cyclin D1 induction could be due to
high levels of toxicity causing irreparable damage to cells as they were cultured over the 3 and 5
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day time periods.
To determine whether cell toxicity was the cause of low levels of induction, we lowered
the quantity of each test agent to 50% of their dosage when tested alone. Under conditions of
200 nm arsenic and 2.8 mJ/cm2 of UVB-irradiation, induction was prevalent with a timedependent increase in induced levels. Although treating NHEK cells with both test agents
demonstrated levels of induction higher than cells treated with arsenic alone, UVB treatment led
to higher induced levels in all with the exception of the cells exposed to agents for 1 day.
Burns et, al. (46) found that ultraviolet radiation led to an increase in the prevalence of
malignant skin tumors in mice that had ingested arsenic. A cause of marked increase in cancer
prevalence we hypothesized could be due to aberrant p53 activity, which alters p21 expression,
leading to unregulated replication and proto-oncogenic mutation. However, although induction
was prevalent, co-treatment did not lead to synergistic potentiation of cyclin D1when compared
to samples exposed to UVB radiation at 5.7 mJ/cm2. Conflicting effects of UVB and arsenic can
also be the cause of lower levels of induction. Arsenic has been shown to lead to increased cell
proliferation whereas UV is linked to blockage of DNA synthesis, allowing DNA repair
(12, 45, 46).
Since it was established that cyclin D1 was induced though treatment with arsenic and
UVB-irradiation, we next set out to determine a possible mechanism leading to induction.
Evidence of hypomethylation of the cyclin D1 promoter region suggests induction of the cyclin
D1 gene (47), due to the greater availability of promoter binding sites. However, complications
arose in analyzing results for this experiment. Although the experimental procedure had yielded
results on occasion, many values were unable to be interpreted. A full chart containing all
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experiments and values can be seen in Appendix IB. Preliminary results had demonstrated that
methylation could be a method of cyclin D1 induction (Appendix IVB, IVC); however the
technique must be adjusted. The bisulfite conversion kit has been documented to lead to DNA
fragmentation, and is a reason for unreadable data, as previously mentioned.
The final goal of our experiment was to create a reporter gene construct that could be
used to quantify activation of the cyclin D1 promoter. Towards this goal, we isolated a segment
of the cyclin D1 promoter region which was then cloned into the luciferase reporter pGL2 and
subsequently transfected into immortalized HEK cells. After testing viability of the transfected
plasmid, cells were treated with our inductive conditions in an attempt to detect altered levels of
cyclin D1 induction indirectly though luciferase activity. Although only one time point was
analyzed, preliminary results have so far demonstrated the utility of this method as a tool for
detecting and quantifying promoter activation effected by a variety of exogenous agents. When
treated with arsenic, we show nearly a 2-fold increase in luminescence after 3 days of treatment.
The next step forward will be to conduct the experiment with our 1 and 5 day time points. The
aim of this experiment will be to create a series of pGL2/cyclin D1 promoter region constructs
with elements removed in a sequential manner. Our goal is to determine which transcription
factor, in the presence of arsenic and UVB, cause induction in cyclin D1.
Going forward, the overarching goal of this project will be:
1. Test cyclin D1 induction over a broad range of agent dosages to determine whether levels of
agents can be found where synergism can be demonstrated.
2. Correlate levels of promoter methylation with induction of cyclin D1 transcription and
promoter activation.
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Yu, et al. (35) found that arsenic and UVB exposure separately lead to apoptosis
independently; arsenic, through the Fas/FasL pathway and UVB through Bcl-2 suppression and
stimulation of caspase-8 activity. This may be part of the reason why our 400 nm treated arsenic,
5.7mJ/cm2 of UVB samples demonstrated poor viability. Hartwig, et al. (36) also found an
increased sensitivity to UV light in cells treated with dose dependent amounts of trivalent and
pentavalent forms of arsenic. On the other hand, Chen, et al. (43) demonstrated that when
keratinocytes were treated with arsenic first followed by UVB at least 24 hours after arsenic
treatment, caspase activity remained dormant. Furthermore, the As/UVB-treated keratinocytes,
when given a 24 hour period before irradiation, demonstrated viability similar to that of
untreated cells (43). This experiment did not test cyclin D1 induction.
The ultimate goal of this project will be to identify the critical promoter elements that
mediate the inductive effects of the two agents. For this a series of constructs lacking specific
promoter transcriptional elements of the cyclin D1 promoter region will be created, and cloned
into the pGL2 reporter. Figure 11 depicts a restriction digestion-based strategy to create nested
deletions used Nagata et al. (13) to identify promoter elements that regulate cyclin D1 expression
in vascular endothelial cells. We will create promoter deletion constructs by gene synthesis
rather than by restriction digestion so that our constructs will contain defined, as opposed to
nested promoter deletions which will allow us to more precisely delineate the critical regions of
the cyclin D1 promoter that mediate the inductive effects of each agent singly or acting
synergistically.
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Figure 11: Diagram of promoter
deletions to determine transcription
elements that interact with arsenic and
UVB to cause induction of cyclin D1.
(Adapted from Nagata, et al. (13)).

In Summary:


Exposure of NHEK to submicromolar levels of arsenic and UVB solar radiation has
demonstrated induction of cyclin D1. Co-treatment has also demonstrated an inductive
effect, but not a potentiated effect.



Data on whether methylation is the mechanic responsible for induction of cyclin D1 have
been inconclusive thus far. Troubleshooting will be performed to identify problems with
this procedure.



Preliminary data has shown that arsenic treatment causes induction of cyclin D1 through
manipulation of the transcriptional regulatory region. Cells treated with UVB do not lead
to the same conclusion, pointing to the idea that induction may be due to other factors.
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Appendix
I.

Raw Data
a. Raw Ct values for Part I.

Results
Condition
As - 1
Day
As - 3
Day
As - 5
Day

2/14/2010
Ind. Ratio

2/14/2010
Ind. Ratio

4/24/2010
Ind. Ratio

7/1/2010
Ind. Ratio

6/23/2010
Ind. Ratio

6/22/2010
Ind. Ratio

6/24/2010
Ind. Ratio

1.08

1.64

1.45

0.83

0.85

0.58

0.92

1.89

1.60

ND

2.22

0.93

0.51

0.78

ND

ND

ND

ND

ND

ND

ND

As+UVB
-1

2.83

2.82

1.39

17.75

0.80

0.73

1.02

As+UVB
-3

1.89

2.48

ND

1.33

0.83

0.37

0.95

ND

ND

ND

ND

ND

ND

ND

0.56

1.25

1.39

2.00

1.10

0.86

1.13

1.63

1.42

ND

1.90

5.24

5.39

6.70

ND

ND

ND

ND

ND

ND

ND

1.39

1.84

ND

ND

ND

ND

ND

1.83

1.57

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

As+UVB
-5
UVB - 1
Day
UVB - 3
Day
UVB - 5
Day
Half - 1
Day
Half - 3
Day
Half - 5
Day
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Results
Condition
As - 1
Day
As - 3
Day
As - 5
Day

6/29/2010
Ind. Ratio

7/2/2010
Ind Ratio

9/29/2010
Ind. Ratio

9/29/2010
Ind. Ratio

10/23/2010
Ind. Ratio

10/23/2010
Ind. Ratio

12/16/2010
Ind. Ratio

0.78

0.94

9.32

9.68

0.94

1.09

1.00

2.72

2.69

10.59

9.29

3.26

1.01

0.89

ND

ND

11.24

9.82

2.03

1.13

1.07

As+UVB
-1

17.88

22.24

ND

ND

ND

0.81

ND

As+UVB
-3

1.65

1.45

ND

ND

ND

0.04

ND

ND

ND

ND

ND

ND

0.04

ND

1.72

2.85

3.78

3.72

ND

ND

1.46

2.02

1.84

20.97

21.26

ND

0.93

1.16

ND

ND

35.51

38.19

1.13

1.20

1.63

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

As+UVB
-5
UVB - 1
Day
UVB - 3
Day
UVB - 5
Day
Half - 1
Day
Half - 3
Day
Half - 5
Day
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Results
Condition
As - 1
Day
As - 3
Day
As - 5
Day

12/17/2010
Ind. Ratio

12/17/2010
Ind. Ratio

12/23/2010
Ind. Ratio

12/28/2010
Ind. Ratio

1/10/2011
Ind. Ratio

2/14/2011
Ind. Ratio

2/14/2011
Ind. Ratio

0.99

1.26

1.19

1.13

0.82

1.90

3.40

0.88

1.07

0.77

1.17

1.19

2.58

4.29

1.06

1.26

0.35

ND

ND

ND

ND

As+UVB
-1

ND

0.71

1.16

1.00

1.06

2.41

4.21

As+UVB
-3

ND

0.97

1.10

1.13

1.09

1.91

3.01

ND

1.56

0.84

ND

ND

ND

ND

1.45

1.50

1.06

1.04

0.98

1.00

2.21

1.15

1.19

1.13

1.10

1.02

2.56

3.22

1.62

1.68

0.60

ND

ND

ND

ND

ND

ND

1.41

1.25

1.24

2.78

3.19

ND

ND

1.40

1.17

1.08

2.44

4.32

ND

ND

1.15

ND

ND

ND

ND

As+UVB
-5
UVB - 1
Day
UVB - 3
Day
UVB - 5
Day
Half - 1
Day
Half - 3
Day
Half - 5
Day
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Results
Condition

12/16/2010
Ind. Ratio

2/16/2011
Ind. Ratio

2/16/2011
Ind. Ratio

3/18/2011
Ind. Ratio

3/18/2011
Ind. Ratio

10/24/2011
Ind. Ratio

As - 1 Day
As - 3 Day
As - 5 Day
As+UVB - 1
As+UVB - 3

1.27
1.08
1.27
ND
ND

1.36
1.30
ND
1.11
1.14

1.32
1.26
ND
1.16
1.08

1.07
ND
0.88
1.10
1.62

ND
1.04
1.21
1.29
ND

ND
0.06
0.05
0.12
ND

As+UVB - 5
UVB - 1 Day
UVB - 3 Day
UVB - 5 Day
Half - 1 Day
Half - 3 Day

ND
0.71
0.98
1.56
ND
ND

ND
1.14
1.25
ND
1.38
0.95

ND
1.44
0.98
ND
1.23
1.81

1.16
ND
ND
ND
1.25
0.74

0.00
1.16
0.91
ND
ND
ND

ND
34.90
51.27
30.91
20.25
25.90

Half - 5 Day

ND

ND

ND

1.09

ND

24.42
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Condition

Average

St. Dev

St. Error

As - 1 Day
As - 3 Day
As - 5 Day
As+UVB - 1 Day
As+UVB - 3 Day
As+UVB - 5 Day

1.87
2.20
2.61
3.98
1.34
0.72

2.36
2.52
3.74
6.52
0.70
0.69

0.37
0.44
0.75
0.57
0.62
1.17

UVB - 1 Day
UVB - 3 Day
UVB - 5 Day
Half - 1 Day
Half - 3 Day
Half - 5 Day

2.93
5.72
11.40
3.38
3.93
8.89

6.86
11.19
16.29
5.64
7.35
13.45

0.55
0.53
0.83
0.22
0.22
0.42

Table Ia: Raw Ct values for real-time PCR experiments in Part I. Values are computed by raising
Ct values to 2-Ct. Computer values have been normalized to equivalent control time points. NDs
are non-determinable, due to 2-Ct computed values equaling 0 or over 2 standard deviations away
from threshold. As = Arsenic, UVB = UVB irradiation, Half = 200 nM arsenic, 2.8mJ/cm2 of
UVB irradiation. Number next to label reflects duration of growth with mutagen.
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b. Raw Ct values for Part II.
Part II Ratios
Control - 1 Day
Control - 3 Day
Control - 5 Day
Arsenic - 1 Day
Arsenic - 3 day
Arsenic - 5 day
UVB - 1 Day
UVB - 3 Day
UVB - 5 Day

Part II Ratios
Control - 1 Day
Control - 3 Day
Control - 5 Day
Arsenic - 1 Day
Arsenic - 3 day
Arsenic - 5 day
UVB - 1 Day
UVB - 3 Day
UVB - 5 Day

3/12/2011
ND
ND
ND
0.21
0.06
0.03
0.12
ND
0.01

3/21/2012
ND
ND
0.00
ND
ND
ND
ND
ND
ND

1/8/2012
0.04
0.35
0.67
0.22
0.32
0.42
0.65
1.31
0.02

4/9/2012
ND
ND
ND
0.22
0.08
ND
0.11
ND
20.61

1/10/2012
0.01
ND
0.00
0.03
0.22
ND
0.14
0.41
0.08

4/9/2012
ND
ND
ND
ND
ND
ND
0.03
0.65

2/25/2012
0.88
ND
0.98
0.58
ND
ND
10.56
3.38
ND

5/28/2012
ND
0.00
0.00
ND
ND
0.00
ND
ND
ND

3/10/2012
0.78
ND
0.00
0.01
0.00
0.00
0.02
0.00
ND

5/29/2012
ND
ND
ND
ND
ND
ND
ND
ND
0.013

3/15/2012
0.00
0.00
ND
ND
ND
ND
ND
ND
ND

Average
0.34
0.12
0.28
0.21
0.14
0.11
1.59
1.27
3.56

St. dev
4.5E-01
2.0E-01
4.4E-01
2.1E-01
1.3E-01
2.1E-01
3.6E+00
1.5E+00
8.4E+00

3/17/2012
ND
ND
ND
ND
ND
ND
1.09
ND
ND

St.Error
2.0E-01
1.2E-01
1.8E-01
8.4E-02
5.8E-02
1.0E-01
1.3E+00
7.5E-01
3.4E+00

Table Ib: Raw Ct values for real time PCR experiments in part II. Values were computed by
raising Ct values to 2-Ct.
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c. Raw Luminescence values Part III.
i. Values for experimental testing of various plasmids
Sample

3/14/2012

5/7/2010

5/10/2012

7/20/2012

8/2/2012

Water

N/A

4.4E+01

3.9E+01

3.3E+01

4.1E+01

- Control

2.9E+01

2.3E+01

4.3E+01

3.0E+01

3.6E+01

+ Control

2.0E+03

2.9E+03

1.9E+03

4.1E+03

1.7E+03

PGL2/CD 1

2.4E+01

2.6E+01

4.5E+01

4.1E+01

4.2E+01

PGL2/CD 2

3.6E+01

4.4E+01

5.9E+01

2.7E+02

1.1E+02

PGL2/CD 3

4.0E+01

7.8E+01

4.3E+01

2.8E+02

6.2E+01

µg of DNA Added

1ug

1ug

1ug

2ug

2ug

Table Ici: Raw values for testing Luciferase activity in various plasmids. Highlighted samples
contained 1ug plasmid (only in positive control).
ii. Values for transfection with experimental conditions.
Part III Values

10/7/2012

10/7/2012

10/7/2012

10/7/2012

- Control

2.7E+01

2.2E+01

2.6E+01

+ Control

1.5E+02

2.0E+02

1.4E+02

Untreated

4.2E+02

4.9E+02

4.4E+02

3.8E+02

Arsenic

7.5E+02

8.6E+02

2.5E+02

7.9E+02

UVB

2.0E+02

2.2E+02

7.4E+01

1.6E+02

µg of DNA Added

2ug

2ug

2ug

2ug

Table Icii: Raw values for preliminary luminescence experiments. Highlighted samples were
omitted due to high deviation.
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II.

Preparation of subcloned PGL2-cyclin D1 promoter region vector.
a. Analytical gel showing cyclin D1 promoter region segment.

AP1L1CYCD1PRR

M1

DFCYCD1PRR

1000
750
500
300
150
50

Figure IIa: PCR results of various regions in the cyclin D1 transcriptional regulatory region.
Highlighted squares refer to primers noted above the well. Marker used was PCR marker.
AP1L1CYCD1PRR = 1080 bp length | DFCYCD1PRR = 1059 bp length
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b. Analytical gel showing synthesized cyclin D1 promoter region segment and PGL2 prior to subcloning.

Figure IIb: Restriction digested cyclin D1 promoter region (red) and PGL-2 (blue) before
excision and gel purification (left) and after (right). 1% agarose gel.
III.

Other relevant experimental data

a. Prior Western blot data of cyclin D1 harvested from arsenic-treated cells.

Figure IVa. Previous data demonstrating induction of cyclin D1 in NHEK treated with NHEK
over 7 days. Induction was visible at all-time points at the 400nM concentration. 7 Day example
shown due to pronounced effect (12).
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b. Analytical Gel of cyclin D1 specific PCR post bisulfate treatment.
PCR
Marker

As5
Untreated

As5
Converted
Figure IVb1: 2% Agarose gel showing a band at the

1000
750
500
300
150
50

186 base pair range for the 5-day arsenic treated cells
before bisulfite conversion, and no band in the same
range for methylated arsenic treated cells.
162 base pairs (Primers cd1meLS2R + cd1meLS2L)

1000
750
500
300
150
50

Figure IVb2: 2% Agarose gel showing samples before and after treatment with the bisulfate
conversion kit. In almost all samples, after conversion, PCR products no longer appeared,
indicating greater modification of non-methylated CpG islands in the promoter groups. These
modifications indicate that more promoter groups would be available during transcription. Left
gel shows samples before bisulfite treatment, right gel shows samples after bisulfite treatment.
Starting from the left, Control, Arsenic 1 day, Arsenic 3 day, Arsenic 5 day, UVB 1 day, UVB 3
day, UVB 5 day. Marker used was PCR marker
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c. Preliminary methylation experimental data.

Figure 3: Preliminary trials demonstrate possible epigenetic effects of mutagenic exposure in
culture and changes in methylation in a time-dependent fashion.

55

References
1. Arnold A, Papanikolaou A. (2005) Cyclin D1 in breast cancer pathogenesis. J Clin
Oncol. 23(18), 4215-4224.
2. Caldon CE, Daly RJ, Sutherland RL, Musgrove EA. (2005) Cell cycle control in breast
cancer cells. J Cell Biochem., [Epub ahead of print]
3. Ozaki S, Ikeda S, Ishizaki Y, Kurihara T, Tokumoto N, Iseki M, Arihiro K, Kataoka T,
Okajima M, Asahara T. (2005) Alterations and correlations of the components in the Wnt
signaling pathway and its target genes in breast cancer. Oncol Rep. 14(6), 1437-1443.
4. Jin LH, Shao QJ, Luo W, Ye ZY, Li Q, Lin SC (2003) Detection of point mutations of
the Axin1 gene in colorectal cancers. Int J Cancer. 107(5), 696-699.
5. Lynch HT, Grady W, Suriano G, Huntsman D. (2005) Gastric cancer: new genetic
developments. J Surg Oncol., 90(3), 114-133.
6. Gomez-Caminero, A., Howe, P., Hughes, M., Kenyon, E., Lewis, D.R., Moore, M., Ng,
J., Aitio A. and Becking, G. (2001). Environmental Health Criteria for Arsenic and
Arsenic compounds, in: The International Programme on Chemical Safety (IPCS), 224,
Chapter 1: Summary, section 4, The World Health Organization press, Geneva
7. Lau, A.T., Li, M., Xie, R., He, Q.Y. and Chiu J.F. (2004). Opposed arsenite-induced
signaling pathways promote cell proliferation or apoptosis in cultured lung cells.
Carcinogenesis 25(1), 21-28.
8. Liao, W.T., Chang, K.L., Yu C.L., Chen, G.S., Chang, L.W. and Yu, H.S. (2004).
Arsenic induces human keratinocyte apoptosis by the FAS/FAS ligand pathway, which
correlates with alterations in nuclear factor-kappa B and activator protein-1 activity. J.
Invest. Dermatol. 122(1), 125-129.
9. Hu, J., Fang, J., Dong, Y., Chen, S.J. and Chen Z. (2005). Arsenic in cancer therapy.
Anticancer Drugs 16(2), 119-127.
10. Sahu, G.R. and Jena, R.K. (2005). Significance of intracellular arsenic trioxide for
therapeutic response in acute promyelocytic leukemia. Am J Hematol. 78(2), 113-116.
11. Wu, F., Burns, F.J., Zhang, R., Uddin, A.N., and `, T.G. (2005) Arsenite-Induced
Alterations of DNA Photodamage Repair and Apoptosis After Solar-Simulation UVR in
Mouse Keratinocytes in Vitro. Environmental Health Perspectives 113(8), 983-986
12. Hwang B.J., Utti, C., and Steinberg, M.L. Induction of cyclin D1 by submicromolar
concentrations of arsenite in human epidermal keratinocytes, Toxicology and Applied
Pharmacology (2006), doi:10.1016/j.taap.2006.08.00

56

13. Daisuke Nagata, Etsu Suzuki, Hiroaki Nishimatsui, Hiroshi Satonaka, Atsuo Goto,
Masao Omata, and Yasunobu Hirata (2001) Transcriptional Activation of the cyclin D1
Gene Is Mediated by Multiple Cis-Elements, Including SP1 Sites and a cAMP-responsive
Element in Vascular Endothelial Cells. J. Biol Chem, 276, 662-669.
14. Schaefer, M., Pollex, T., Hanna K., and Lyko F. (2008) RNA cytosine methylation
analysis by bisulfite Sequencing Nucleic Acids Research, 2009, 37(2) 1-10
15. Ikehata H., Ono T., Significance of CpG methylation for solar UV-induced mutagenesis
and carcinogenesis in skin. Photochem Photobiol. 2007 Jan-Feb;83(1):196-204.
16. Dart, RC (2004). Medical toxicology. Philadelphia: Williams & Wilkins. pp. 1393–1401.
ISBN 0-7817-2845-2.
17. Curry, A., Carrin, G., Bartram, J., Yamamura, S., Heijnen, H., Sims, J., ... & Sato, Y.
(2000). Towards an assessment of the socioeconomic impact of arsenic poisoning in
Bangladesh. World Health Organization.
18. Smith, A. H., Lingas, E. O., & Rahman, M. (2000). Contamination of drinking-water by
arsenic in Bangladesh: a public health emergency. Bulletin of the World Health
Organization, 78(9), 1093-1103.
19. Reichard, J. F., & Puga, A. (2010). Effects of arsenic exposure on DNA methylation and
epigenetic gene regulation. Epigenomics, 2(1), 87-104.E
20. City of Tucson's Environmental Management Division. (2012, November 04).
Health & safety in the arts. Retrieved from
http://www.ci.tucson.az.us/arthazards/paint1.html
21. Marte, F., Pequignot, A., & von Endt, D. W. (2006). Arsenic in taxidermy collections:
history, detection, and management. In Collection Forum (Vol. 21, No. 1-2, pp. 143150).
22. Mandal, Badal Kumar; Suzuki, K. T. (2002). "Arsenic round the world: a
review". Talanta 58 (1): 201–235. DOI:10.1016/S0039-9140(02)002680. PMID 18968746.
23. Wisconsin Department of Health Services. (2012, August 08). Lead arsenate pesticides.
Retrieved from http://www.dhs.wisconsin.gov/eh/hlthhaz/fs/LeadArPest.htm
24. Westing, A. H. (1972). Herbicides in war: Current status and future doubt. Biological
Conservation, 4(5), 322-327.29
25. Hileman, B. (2007). Arsenic in chicken production. Chem. Eng. News, 85(15), 34-35.
26. Cone, M. (2011, October 03). Many u.s. drinking water wells contaminated with arsenic,
other elements. Retrieved from Scientific American

57

27. Mandal, B. K., & Suzuki, K. T. (2002). Arsenic round the world: a review.Talanta, 58(1),
201-235.
28. Gregus, Z., Roos, G., Geerlings, P., & Németi, B. (2009). Mechanism of Thiol-Supported
Arsenate Reduction Mediated by Phosphorolytic-Arsenolytic Enzymes II. Enzymatic
Formation of Arsenylated Products Susceptible for Reduction to Arsenite by
Thiols. Toxicological Sciences, 110(2), 282-292.
29. Gregus, Z., & Németi, B. (2002). Purine nucleoside phosphorylase as a cytosolic arsenate
reductase. Toxicological Sciences, 70(1), 13-19.
30. Németi, B., & Gregus, Z. (2007). Glutathione-dependent reduction of arsenate by
glycogen phosphorylase—A reaction coupled to glycogenolysis.Toxicological
sciences, 100(1), 36-43.
31. Zhao, C. Q., Young, M. R., Diwan, B. A., Coogan, T. P., & Waalkes, M. P. (1997).
Association of arsenic-induced malignant transformation with DNA hypomethylation and
aberrant gene expression. Proceedings of the National Academy of Sciences, 94(20),
10907-10912.
32. Reichard, J. F., Schnekenburger, M., & Puga, A. (2007). Long term low-dose arsenic
exposure induces loss of DNA methylation. Biochemical and biophysical research
communications, 352(1), 188-192.
33. Armstrong, B. K., & Kricker, A. (2001). The epidemiology of UV induced skin
cancer. Journal of Photochemistry and Photobiology B: Biology, 63(1), 8-18.
34. Christophers, A. J. (1998). Melanoma is not caused by sunlight. Mutation
Research/Fundamental and Molecular Mechanisms of Mutagenesis, 422(1), 113-117.
35. Yu, H. S., Liao, W. T., & Chai, C. Y. (2006). Arsenic carcinogenesis in the skin. Journal
of biomedical science, 13(5), 657-666.
36. Hartwig, A., Groblinghoff, U. D., Beyersmann, D., Natarajan, A. T., Filon, R., &
Mullenders, L. H. (1997). Interaction of arsenic (III) with nucleotide excision repair in
UV-irradiated human fibroblasts. Carcinogenesis, 18(2), 399-405.
37. Lee, C. H., Yu, C. L., Liao, W. T., Kao, Y. H., Chai, C. Y., Chen, G. S., & Yu, H. S.
(2004). Effects and interactions of low doses of arsenic and UVB on keratinocyte
apoptosis. Chemical research in toxicology, 17(9), 1199-1205.
38. Liu, S., Gonzalez, J., Hwang, B. J., & Steinberg, M. L. (2011). Induction of Cyclin D1 by
Arsenite and UVB-irradiation in Human Keratinocytes. Journal of health care for the
poor and underserved, 22(5), 110-121.
39. Hwang, B. J., Utti, C., & Steinberg, M. (2006). Induction of cyclin D1 by submicromolar
concentrations of arsenite in human epidermal keratinocytes.Toxicology and applied
pharmacology, 217(2), 161-167.
58

40. Fu, M., Wang, C., Li, Z., Sakamaki, T., & Pestell, R. G. (2004). Minireview: Cyclin D1:
normal and abnormal functions. Endocrinology, 145(12), 5439-5447.
41. El-Abaseri, T. B., Putta, S., & Hansen, L. A. (2006). Ultraviolet irradiation induces
keratinocyte proliferation and epidermal hyperplasia through the activation of the
epidermal growth factor receptor. Carcinogenesis, 27(2), 225-231.
42. Wu, C.-S., Yu, C.-L., Wu, C.-S., Lan, C.-C. E. and Yu, H.-S. (2004), Narrow-band
ultraviolet-B stimulates proliferation and migration of cultured melanocytes.
Experimental Dermatology, 13: 755–763. doi: 10.1111/j.0906-6705.2004.00221.x
43. Chen, P. H., Lan, C. C. E., Chiou, M. H., Hsieh, M. C., & Chen, G. S. (2005). Effects of
arsenic and UVB on normal human cultured keratinocytes: impact on apoptosis and
implication on photocarcinogenesis. Chemical research in toxicology, 18(2), 139-144.
44. Nanney, D. L. (1958). Epigenetic control systems. Proceedings of the National Academy
of Sciences of the United States of America, 44(7), 712.
45. Burns, F. J., Uddin, A. N., Wu, F., Nádas, A., & Rossman, T. G. (2004). Arsenic-induced
enhancement of ultraviolet radiation carcinogenesis in mouse skin: a dose-response
study. Environmental health perspectives, 112(5), 599.
46. Rossman, T. G., Uddin, A. N., & Burns, F. J. (2004). Evidence that arsenite acts as a
cocarcinogen in skin cancer. Toxicology and applied pharmacology,198(3), 394-404.
47. Alao, J. P. (2007). The regulation of cyclin D1 degradation: roles in cancer development
and the potential for therapeutic invention. Molecular cancer, 6(1), 24.
48. Brash, D. E., Rudolph, J. A., Simon, J. A., Lin, A., McKenna, G. J., Baden, H. P., ... &
Ponten, J. (1991). A role for sunlight in skin cancer: UV-induced p53 mutations in
squamous cell carcinoma. Proceedings of the National Academy of Sciences, 88(22),
10124-10128. Setlow, R. B., Grist, E., Thompson, K., & Woodhead, A. D. (1993).
Wavelengths effective in induction of malignant melanoma. Proceedings of the National
Academy of Sciences, 90(14), 6666-6670.
49. Wikonkal, N. M., & Brash, D. E. (1999, September). Ultraviolet radiation induced
signature mutations in photocarcinogenesis. In Journal of Investigative Dermatology
Symposium Proceedings (Vol. 4, No. 1, pp. 6-10). Nature Publishing Group.
50. Oregon State University. (2011, June 22). Micronutrient information center. Retrieved
from http://lpi.oregonstate.edu/infocenter/vitamins/vitaminD/
51. World Health Organization: Media Centre. (2009, Dec). Ultraviolet radiation and human
health. Retrieved from http://www.who.int/mediacentre/factsheets/fs305/en/index.html
52. Junttila, M. R., & Evan, G. I. (2009). p53—a Jack of all trades but master of none.
Nature Reviews Cancer, 9(11), 821-829.

59

53. Ji, F., Pierre, Z., Liu, S., Hwang, B. J., Hill, H. Z., Hubbard, K., & Steinberg, M. (2006).
Novel mitochondrial deletions in human epithelial cells irradiated with an FS20
ultraviolet light source in vitro. Journal of Photochemistry and Photobiology A:
Chemistry, 184(3), 340-346.
54. Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991). p53 mutations in
human cancers. Science (New York, NY), 253(5015), 49.
55. Stephen F. Altschul, Thomas L. Madden, Alejandro A. Schäffer, Jinghui Zhang, Zheng
Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a
new generation of protein database search programs",
Ascension: Z29078.1Nucleic Acids Res. 25:3389-3402.
56. Stephen F. Altschul, Thomas L. Madden, Alejandro A. Schäffer, Jinghui Zhang, Zheng
Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a
new generation of protein database search programs",
Ascension: NG_007375 Nucleic Acids Res. 25:3389-3402.
57. Rossman, T. G. (2003). Mechanism of arsenic carcinogenesis: an integrated
approach. Mutation research, 533(1-2), 37-65.
58. Walsh, C., & Xu, G. (2006). Cytosine methylation and DNA repair. DNA Methylation:
Basic Mechanisms, 283-315.
59. Thermo Fisher Scientific Inc. (2013). Luciferase Reporters. Retrieved from:
http://www.piercenet.com/browse.cfm?fldID=5ED78F45-0A64-A63D-7E321C61D6B86112
60. Promega Corporation. (2013). pGL2-Basic Gene. Retrieved from:
http://www.promega.com/~/media/images/resources/figures/03000399/0313vbw4.gif?la=en

60

